Immunogenicity of a Fourth Dose of Haemophilus influenzae Type b (Hib) Conjugate Vaccine and Antibody Persistence in Young Children from the United Kingdom Who Were Primed with Acellular or Whole-Cell Pertussis Component-Containing Hib Combinations in Infancy
Open Access
- 1 October 2007
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (10) , 1328-1333
- https://doi.org/10.1128/cvi.00191-07
Abstract
In response to the rising incidence of Haemophilus influenzae type b (Hib) disease in the United Kingdom, a national campaign to give a booster dose of single-antigen Hib conjugate vaccine to children aged 6 months to 4 years was undertaken in 2003. Children (n = 386) eligible for Hib vaccine in the campaign were recruited. Hib antibody concentrations were measured before boost and at 1 month, 6 months, 1 year, and 2 years after boost and were analyzed according to children's ages at booster dose and whether a Hib combination vaccine containing acellular pertussis (aP) or whole-cell pertussis (wP) components was given in infancy. The geometric mean antibody concentrations (GMCs) before the booster declined as the time since primary immunization increased (P < 0.001), and GMCs were threefold higher in recipients of wP-Hib than aP-Hib combination vaccines (P < 0.001). GMCs 1 month after the booster increased with age (P < 0.001) as follows: 6 to 11 months; 30 μg/ml (95% confidence interval [CI], 22 to 40); 12 to 17 months, 68 μg/ml (95% CI, 38 to 124); and 2 to 4 years, 182 μg/ml (151 to 220), with no difference according to the type of priming vaccine received. Antibody levels declined after the booster, but 2 years later, GMCs were more than 1.0 μg/ml for all age groups. By extrapolating data for the decline in antibody levels, we found the GMCs 4 years after boosting were predicted to be 0.6, 1.4, and 2.6 μg/ml for those boosted at 6 to 11 months, 12 to 17 months, and 2 to 4 years, respectively, with levels of at least 0.15 μg/ml in about 90% of individuals. A booster dose of Hib vaccine given after the first year of life should provide long-lasting protection.Keywords
This publication has 24 references indexed in Scilit:
- Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of ageArchives of Disease in Childhood, 2007
- Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: Safety, immunogenicity and persistence of antibody responsesVaccine, 2006
- Haemophilus influenzaeType b Reemergence after Combination ImmunizationEmerging Infectious Diseases, 2006
- Maintenance of Serological Memory by Polyclonal Activation of Human Memory B CellsScience, 2002
- Haemophilus influenzae Type b Vaccine: Reconstitution of Lyophilised PRP-T Vaccine with a Pertussis-containing Paediatric Combination Vaccine, or a Change in the Primary Series Immunisation Schedule, May Modify the Serum Anti-PRP Antibody ResponsesCurrent Medical Research and Opinion, 2001
- Haemophilus influenzaeType b Vaccine: Reconstitution of Lyophilised PRP-T Vaccine with a Pertussis-containing Paediatric Combination Vaccine, or a Change in the Primary Series Immunisation Schedule, May Modify the Serum Anti-PRP Antibody ResponsesCurrent Medical Research and Opinion, 2001
- The Induction of Immunologic Memory after Vaccination withHaemophilus influenzaeType b Conjugate and Acellular Pertussis–Containing Diphtheria, Tetanus, and Pertussis Vaccine CombinationThe Journal of Infectious Diseases, 1999
- The Impact Of Conjugate Vaccine On Carriage Of Haemophilus Influenzae Type BThe Journal of Infectious Diseases, 1995
- Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-TThe Lancet, 1994
- Distinct short‐lived and long‐lived antibody‐producing cell populationsEuropean Journal of Immunology, 1986